Comment on “Fingolimod effects on left ventricular function in multiple sclerosis” Mult Scler 2015

Abstract

Get full access to this article

View all access options for this article.

References

Racca

Di Rienzo

Cavarretta

. Fingolimod effects on left ventricular function in multiple sclerosis. Mult Scler 2016; 22: 201–211.

Calabresi

Radue

Goodin

. Safety and efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545–556.

Data on file, Novartis Pharma AG, Basel, Switzerland.

Camm

Hla

Bakshi

. Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications. Am Heart J 2014; 168: 632–644.

Levkau

. Cardiovascular effects of sphingosine-1-phosphate (S1P). Handb Exp Pharmacol 2013: 147–170.